Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains

被引:23
作者
Goudsmit, J
Weverling, GJ
van der Hoek, L
de Ronde, A
Miedema, F
Coutinho, RA
Lange, JMA
Boerlijst, MC
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Populat Biol Sect, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Municipal Hlth Serv, Dept Publ Hlth & Environm, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, CLB Sanquin Blood Supply Fdn, Lab Expt & Clin Immunol, NL-1105 AZ Amsterdam, Netherlands
[6] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
关键词
HIV; resistance mutations; zidovudine; mathematical model; transmission;
D O I
10.1097/00002030-200111230-00011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Because maintenance of treatment success in HIV-1 infection requires viruses to remain therapy sensitive in drug-naive seropositive persons, we looked at the primary infections caused by drug-resistant HIV-1 over time. Furthermore, to study the coverage rate of therapy and therapy failure in relation to the transmission of resistant viruses a mathematical model was developed. Design: The reverse transcriptase and protease genes of viruses were analysed in newly infected people in the period 1990-1998 in the Amsterdam Cohort Study on HIV infection and AIDS in homosexual men. Methods: The mathematical model was based on the coverage of drug regimens selecting zidovudine (ZDV) resistance, the lag time in which resistance is gained or lost, the death rate of people infected with resistant virus, and the replacement of resistance-selecting regimens by more potent treatments that substantially reduce viral load and mortality. Results: Of 43 individuals with a primary HIV-infection, three (7%) harboured ZDV-resistant viruses. The first of the ZDV-resistant strains was transmitted in 1995, the last two in 1996. The build-up of ZDV resistance was described by the mathematical model indicating that the equilibrium level of resistance due to treatment depends only on the treatment rate and the outflow rate of patients with resistance virus. Conclusions: Our model indicates that the frequency of viral resistance in a population is determined largely by the number of individuals on insufficient or failing therapy and is influenced only modestly by secondary transmission of ZDV-resistant strains. (C) 2001 Uppincott Williams Wilkins.
引用
收藏
页码:2293 / 2301
页数:9
相关论文
共 39 条
  • [1] Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
  • [2] [Anonymous], CLIN INFECT DIS
  • [3] A tale of two futures: HIV and antiretroviral therapy in San Francisco
    Blower, SM
    Gershengorn, HB
    Grant, RM
    [J]. SCIENCE, 2000, 287 (5453) : 650 - 654
  • [4] RAPID AND SIMPLE METHOD FOR PURIFICATION OF NUCLEIC-ACIDS
    BOOM, R
    SOL, CJA
    SALIMANS, MMM
    JANSEN, CL
    WERTHEIMVANDILLEN, PME
    VANDERNOORDAA, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (03) : 495 - 503
  • [5] ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS
    BOUCHER, CAB
    OSULLIVAN, E
    MULDER, JW
    RAMAUTARSING, C
    KELLAM, P
    DARBY, G
    LANGE, JMA
    GOUDSMIT, J
    LARDER, BA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) : 105 - 110
  • [6] HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
    BrunVezinet, F
    Boucher, C
    Loveday, C
    Descamps, D
    Fauveau, V
    Izopet, J
    Jeffries, D
    Kaye, S
    Krzyanowski, C
    Nunn, A
    Schuurman, R
    Seigneurin, JM
    Tamalet, C
    Tedder, R
    Weber, J
    Weverling, GJ
    Aber, V
    Aboulker, JP
    Babiker, AG
    Bragman, K
    Breckenridge, AM
    Carbon, C
    Charreau, I
    Chene, G
    Collis, P
    Cooper, D
    Darbyshire, JH
    Dormont, J
    Fiddian, P
    Flepp, M
    Gazzard, B
    Goebel, FD
    Hooker, M
    Lange, J
    Luthy, R
    Peto, TEA
    Reiss, P
    Seligmann, M
    Stone, AB
    Thomis, J
    Vella, S
    Walckenaer, G
    Warrell, D
    Weller, IVD
    Wilber, R
    Yeni, P
    Yeo, J
    Withnall, R
    Babiker, A
    Bloch, J
    [J]. LANCET, 1997, 350 (9083) : 983 - 990
  • [7] Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
    de Jong, JJ
    Goudsmit, J
    Lukashov, VV
    Hillebrand, ME
    Baan, E
    Huismans, R
    Danner, SA
    ten Veen, JH
    de Wolf, F
    Jurriaans, S
    [J]. AIDS, 1999, 13 (01) : 75 - 80
  • [8] Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
    de Ronde, A
    van Dooren, M
    van der Hoek, L
    Bouwhuis, D
    de Rooij, E
    van Gemen, B
    de Boer, R
    Goudsmit, J
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (02) : 595 - 602
  • [9] Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
  • [10] DEWOLF F, 1988, LANCET, V1, P373